This study compared two treatment regimes for HER2 positive breast cancer; pyrotinib (Irene) plus vinorelbine (Navelbine), or lapatinib (Tykerb) plus capecitabine (Xeloda). It found that pyrotinib plus vinorelbine (PV) improved survival without cancer progressing compared to lapatinib plus capecitabine (LC). 

This study looked at the use of colchicine (Colcrys) in patients with coronary artery disease (CAD). It found that colchicine reduced the risk of heart attack and stroke in these patients. 

This study evaluated the use of high-dose glucocorticoids (GCs) and their impact on the survival outcomes during anti-PD-1 therapy for the treatment of patients with advanced melanoma. The data showed that early high-dose GC use was associated with poorer outcomes after the onset of immune-related side effects.

This study assessed the effectiveness of netupitant/palonosetron (NEPA; Akynzeo) in preventing nausea and vomiting in patients with multiple myeloma (MM) while receiving high-dose melphalan (HDM; Alkeran) and autologous stem cell transplantation (ASCT). The data showed that NEPA, without dexamethasone (DXM; Decadron), was well-tolerated and effective in preventing nausea and vomiting in patients with MM that received HDM, then ASCT.

This study compared the effectiveness and safety outcomes of platinum-based chemotherapy and immune checkpoint inhibitors (ICIs) for the treatment of patients with early-stage triple-negative breast cancer (TNBC). The data showed that ICI plus chemotherapy was associated with good outcomes with reduced side effects compared with platinum-based chemotherapy in these patients.

This study investigated the role of PET/CT scanning in the treatment of patients with recurrent or hard-to-treat B-cell non-Hodgkin’s lymphoma (NHL) after T-cell therapy. This study found that PET/CT scanning helped predict the effectiveness and side effects of treatment for these patients.

This study looked at the use of high-dose statin treatment before percutaneous coronary intervention (PCI) in patients with coronary artery disease (CAD). It found that patients who received high-dose statin treatment before PCI were less likely to have a major cardiovascular event (MACE) defined as a heart attack or stroke in the next 30 days.

This study looked at the skin-related side effects of immune checkpoint inhibitors in the treatment of melanoma. It found that the most common side effects were mild-to-moderate itching, rash, and vitiligo (loss of skin pigment).  

This study looked at how motor symptoms progressed in patients with Parkinson's disease (PD), before and during the COVID-19 pandemic. It found that motor symptoms progressed more quickly during the first 15 months of the pandemic than during the 15 months before it.

This study looked at the use and response of the Pfizer BioNTech COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma (NHL). It found that patients with NHL undergoing treatment with rituximab (Rituxan)/obinutuzumab (Gazyva) had a poorer immune response to this vaccine, compared to patients without lymphoma.